Tolebrutinib lowers risk of disability progression in secondary MS
MELBOURNE: Tolebrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, a treatment that specifically targets immune
MELBOURNE: Tolebrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, a treatment that specifically targets immune
FEATURED
Recruitment boost to tackle backlog in vital disability work scheme
Disabled people face a “hostile” work environment say MPs
National Disability Insurance Scheme never been gravy train
Expert diagnosis is critical to distinguish ADHD from anxiety
‘Life-changing’ surf therapy program launched to help female veterans
Perimenopause can unravel women with undiagnosed ADHD claims podcast